Brian L Block, MD
Pulmonary Disease · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 1 carrier
- Offices
- 3
- Since medical school
- 14 years
- Harvard Medical School, 2012
Offices
3 locations · University of California San Francisco · Regents of the University of California · University Anesthesia Medical Group
Looking this up.
Hospitals listed: UCSF Medical Center. That is not proof they admit you there this week.
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Block’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A142233 · Current
Licensed to practise in California · since 2016 · expires 2027-10-31 · Harvard Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Critical Care Medicine
- American Board of Internal Medicine - Internal Medicine
- American Board of Internal Medicine - Pulmonary Disease
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for UCSF Medical Center
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.9 (3.79 to 6.02) · 7,590 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.8 (11.3 to 14.4) · 2,019 cases | Worse | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 139.4 (110.22 to 168.58) · 452 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.622 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.626 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.491 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 2,336 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.58 to 1.9) · 4,689 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.89 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 85 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.1 · 132 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.6 · 454 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 618 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 380 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.7 · 5,000 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.06 to 0.38) · 15,965 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.05 to 0.35) · 17,859 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.85 (0 to 1.83) · 4,184 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2 (1.1 to 2.9) · 6,516 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.35 (4.49 to 10.21) · 3,989 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5 (3.22 to 6.77) · 4,087 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.95 (0.74 to 3.15) · 2,034 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.95 (0.63 to 1.28) · 15,431 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 399 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.899 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.689 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.224 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16 · 156 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20 · 564 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 60.3 · 160 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -9.7 · 550 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 44.1 · 660 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 667 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (4.8 to 6.7) · 2,019 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6 · 421 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.9 (11.3 to 17.1) · 3,247 cases | No different | Jan 2022 – Dec 2024 |
What patients said (3,181 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$69,847
Medicare paid this office $69,847 for 439 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 112 | $21,445 | $118 |
| Critical care, first 30-74 minutes | 51 | $18,624 | $184 |
| Return visit (30+ min) | 58 | $5,590 | $86 |
| Critical care, each additional 30 minutes | 15 | $3,248 | $93 |
| Long return visit (40+ min) | 16 | $2,879 | $169 |
See all 15 services
| Long return visit (40+ min) | 112 | $21,445 | $118 |
| Critical care, first 30-74 minutes | 51 | $18,624 | $184 |
| Return visit (30+ min) | 58 | $5,590 | $86 |
| Critical care, each additional 30 minutes | 15 | $3,248 | $93 |
| Long return visit (40+ min) | 16 | $2,879 | $169 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 119 | $2,782 | $15 |
| New patient visit (60+ min) | 13 | $2,100 | $162 |
| Test to measure expiratory airflow and volume | 174 | $1,323 | $7 |
| Test to examine how well the lungs exchange gases | 101 | $771 | $7 |
| Test for exercise-induced lung stress | 27 | $542 | $19 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 16 | $494 | $25 |
| Insertion of artery tube for blood sampling or infusion through skin | 12 | $448 | $34 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 21 | $327 | $15 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 18 | $162 | $9 |
| Online digital evaluation and management service for an established patient for up to 7 days, total time 5-10 minutes | 11 | $125 | $10 |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Insertion of artery tube for blood sampling or infusion through skin | – | – | – | – | 15 | 13 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | – | – | – | 14 | – | – |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
439 Original Medicare patients in 2024. Average age 71 · Under 65 18% · 85 and older 8% · Women 48% · Also on Medicaid 37% · Health risk score 2.84. Above the middle of the specialty; the typical pulmonary disease clinician is at 2.13.
Conditions among them: High blood pressure 75% · COPD 49% · Chronic kidney disease 43% · Diabetes 39% · Coronary heart disease 39% · Heart failure 36% · Atrial fibrillation 31% · Depression 30% · Cancer 22% · Stroke 12% · Dementia 10%.
The office billed $486,272, Medicare allowed $90,366 and paid $69,847; for 1,137 services of 40 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 439 | 1,137 | 71 | 2.84 | $486,272 | $69,847 |
| 2023 | 489 | 1,090 | 71 | 2.53 | $489,976 | $66,675 |
| 2022 | 400 | 972 | 70 | 2.45 | $598,761 | $80,749 |
| 2021 | 319 | 842 | 71 | 2.55 | $514,876 | $75,836 |
| 2020 | 275 | 585 | 69 | 2.53 | $294,058 | $41,908 |
| 2019 | 111 | 224 | 67 | 2.80 | $105,785 | $15,467 |
| 2018 | 17 | 34 | 71 | 2.31 | $40,020 | $5,200 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 13 services
| Critical care, first 30-74 minutes | 57 | $21,797 | $188 |
| Long return visit (40+ min) | 89 | $18,076 | $121 |
| New patient visit (60+ min) | 48 | $7,303 | $152 |
| Return visit (30+ min) | 33 | $2,719 | $80 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 15 | $2,375 | $108 |
| Test to measure expiratory airflow and volume | 259 | $2,053 | $7 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 38 | $1,915 | $28 |
| Critical care, each additional 30 minutes | 11 | $1,711 | $95 |
| Test to examine how well the lungs exchange gases | 162 | $1,286 | $8 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 12 | $1,005 | $72 |
| Test for exercise-induced lung stress | 37 | $688 | $19 |
| Insertion of artery tube for blood sampling or infusion through skin | 15 | $577 | $38 |
| Test to determine lung volumes using sensors | 15 | $139 | $9 |
2022: 13 services
| Critical care, first 30-74 minutes | 77 | $37,988 | $191 |
| Long return visit (40+ min) | 68 | $12,038 | $120 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 39 | $6,203 | $91 |
| New patient visit (60+ min) | 31 | $4,800 | $155 |
| Critical care, each additional 30 minutes | 20 | $4,236 | $96 |
| Return visit (30+ min) | 31 | $2,591 | $76 |
| Extended patient service without direct patient contact, first hour | 15 | $1,995 | $95 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 30 | $1,705 | $28 |
| Test to measure expiratory airflow and volume | 172 | $1,285 | $7 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $1,146 | $64 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 13 | $1,025 | $73 |
| Test to examine how well the lungs exchange gases | 91 | $699 | $8 |
| Test for exercise-induced lung stress | 22 | $438 | $20 |
2021: 11 services
| Critical care, first 30-74 minutes | 47 | $29,217 | $196 |
| Long return visit (40+ min) | 84 | $19,410 | $127 |
| New patient visit (60+ min) | 38 | $5,755 | $151 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 28 | $4,311 | $94 |
| Critical care, each additional 30 minutes | 11 | $3,644 | $98 |
| Return visit (30+ min) | 29 | $2,853 | $89 |
| Extended patient service without direct patient contact, first hour | 18 | $2,306 | $96 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 28 | $1,382 | $29 |
| Test to measure expiratory airflow and volume | 134 | $1,041 | $7 |
| Test to examine how well the lungs exchange gases | 81 | $651 | $8 |
| Test for exercise-induced lung stress | 20 | $409 | $20 |
2020: 8 services
| Critical care, first 30-74 minutes | 40 | $18,447 | $198 |
| New patient visit (60+ min) | 42 | $6,305 | $150 |
| Long return visit (40+ min) | 48 | $6,098 | $97 |
| Extended patient service without direct patient contact, first hour | 22 | $3,148 | $102 |
| Test to measure expiratory airflow and volume | 135 | $1,064 | $7 |
| Test to examine how well the lungs exchange gases | 80 | $637 | $8 |
| Test for exercise-induced lung stress | 22 | $415 | $19 |
| Test to determine lung volumes using sensors | 18 | $133 | $7 |
2019: 4 services
| Critical care, first 30-74 minutes | 28 | $9,829 | $189 |
| Test to measure expiratory airflow and volume | 63 | $470 | $7 |
| Test to examine how well the lungs exchange gases | 25 | $203 | $8 |
| Test to determine lung volumes using sensors | 17 | $187 | $11 |
2018: 1 service
| Critical care, first 30-74 minutes | 11 | $4,660 | $194 |
Medicaid work
$3,622 in 2024
Medicaid paid $3,622 for 134 billed services this clinician did in 2024, up to 43 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 15 | $2,447 |
| Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation | 88 | $849 |
| PULMONARY STRESS TESTING | 14 | $165 |
| Diffusing capacity | 17 | $161 |
| 2024 | 134 | 4 | 43 | $3,622 |
| 2023 | 246 | 3 | 51 | $9,134 |
| 2022 | 126 | 2 | 33 | $1,102 |
| 2021 | 109 | 2 | 22 | $8,100 |
| 2020 | 111 | 2 | 34 | $882 |
| 2019 | 79 | 2 | 23 | $5,564 |
See the largest Medicaid services in earlier years
2023
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 22 | $7,052 |
| Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation | 162 | $1,490 |
| Diffusing capacity | 62 | $592 |
2022
| Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation | 95 | $830 |
| Diffusing capacity | 31 | $271 |
2021
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 39 | $7,541 |
| Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation | 70 | $558 |
2020
| Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation | 80 | $639 |
| Diffusing capacity | 31 | $243 |
2019
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 42 | $5,275 |
| Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation | 37 | $289 |
Drugs they prescribed that Part D paid
$388,565
Pharmacies billed $388,565 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 550) in 2024. At or below the middle of the specialty; the typical pulmonary disease clinician is at 0%.
0 generic and 321 brand-name prescriptions · $388,565 in drug cost · 29 antibiotic prescriptions to 23 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Dupixent | 21 | $89,094 | $4,243 |
| Xolair | 12 | $59,505 | $4,959 |
| Trelegy Ellipta | 42 | $28,964 | $690 |
| Stiolto Respimat | 50 | $26,107 | $522 |
| Anoro Ellipta | 30 | $20,804 | $693 |
See all 17 drugs
| Dupixent | 21 | $89,094 | $4,243 |
| Xolair | 12 | $59,505 | $4,959 |
| Trelegy Ellipta | 42 | $28,964 | $690 |
| Stiolto Respimat | 50 | $26,107 | $522 |
| Anoro Ellipta | 30 | $20,804 | $693 |
| Spiriva Respimat | 14 | $13,437 | $960 |
| Symbicort | 23 | $7,715 | $335 |
| Breyna | 16 | $4,203 | $263 |
| Pulmicort Flexhaler | 13 | $3,504 | $270 |
| Wixela Inhub | 25 | $2,850 | $114 |
| Albuterol Sulfate Hfa | 54 | $1,617 | $30 |
| Ventolin Hfa | 13 | $712 | $55 |
| Prednisone | 31 | $360 | $12 |
| Omeprazole | 12 | $189 | $16 |
| Montelukast | 30 | $122 | $4 |
| Amitriptyline | 17 | $75 | $4 |
| Azithromycin | 12 | $63 | $5 |
Year by year
| 2024 | 550 | 101 | 0% (0) | 58% | $388,565 |
| 2023 | 345 | 97 | 0% (0) | 61% | $210,179 |
| 2022 | 292 | 54 | 0% (0) | 64% | $107,371 |
| 2021 | 273 | 53 | 0% (0) | 62% | $79,303 |
| 2020 | 116 | 31 | 0% (0) | 71% | $30,302 |
| 2019 | 144 | 25 | 0% (0) | 81% | $68,006 |
| 2018 | 311 | 34 | 0% (0) | 75% | $114,386 |
| 2017 | 203 | 35 | 0% (0) | 60% | $52,189 |
| 2016 | 856 | 46 | None | 25% | $63,510 |
| 2015 | 1,501 | 55 | None | 24% | $100,849 |
| 2014 | 1,208 | 65 | None | 26% | $82,836 |
| 2013 | 876 | 50 | 0% (0) | 25% | $46,965 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 13 drugs
| Xolair | 22 | $46,845 | $2,129 |
| Trelegy Ellipta | 33 | $31,166 | $944 |
| Stiolto Respimat | 38 | $21,957 | $578 |
| Anoro Ellipta | 13 | $8,960 | $689 |
| Eliquis | 12 | $7,241 | $603 |
| Incruse Ellipta | 12 | $5,921 | $493 |
| Symbicort | 12 | $5,395 | $450 |
| Wixela Inhub | 11 | $1,774 | $161 |
| Ventolin Hfa | 13 | $789 | $61 |
| Albuterol Sulfate Hfa | 11 | $335 | $30 |
| Fluticasone Propionate | 11 | $272 | $25 |
| Amoxicillin-Clavulanate Potass | 14 | $233 | $17 |
| Prednisone | 20 | $170 | $9 |
2022: 9 drugs
| Stiolto Respimat | 44 | $21,777 | $495 |
| Anoro Ellipta | 33 | $20,057 | $608 |
| Trelegy Ellipta | 15 | $11,004 | $734 |
| Symbicort | 23 | $9,685 | $421 |
| Eliquis | 13 | $6,896 | $530 |
| Albuterol Sulfate Hfa | 18 | $935 | $52 |
| Azithromycin | 14 | $214 | $15 |
| Omeprazole | 14 | $214 | $15 |
| Fluticasone Propionate | 13 | $170 | $13 |
2021: 9 drugs
| Stiolto Respimat | 51 | $25,126 | $493 |
| Anoro Ellipta | 28 | $17,505 | $625 |
| Trelegy Ellipta | 16 | $10,133 | $633 |
| Spiriva Respimat | 13 | $6,292 | $484 |
| Albuterol Sulfate Hfa | 25 | $1,102 | $44 |
| Ventolin Hfa | 13 | $765 | $59 |
| Omeprazole | 15 | $214 | $14 |
| Azithromycin | 11 | $214 | $19 |
| Prednisone | 14 | $124 | $9 |
2020: 3 drugs
| Stiolto Respimat | 12 | $6,812 | $568 |
| Albuterol Sulfate Hfa | 19 | $796 | $42 |
| Ventolin Hfa | 13 | $766 | $59 |
2019: 6 drugs
| Advair Diskus | 16 | $14,272 | $892 |
| Spiriva | 28 | $14,141 | $505 |
| Incruse Ellipta | 15 | $8,775 | $585 |
| Breo Ellipta | 13 | $4,769 | $367 |
| Ventolin Hfa | 13 | $871 | $67 |
| Azithromycin | 12 | $414 | $35 |
2018: 9 drugs
| Advair Diskus | 36 | $22,986 | $638 |
| Spiriva | 34 | $14,689 | $432 |
| Symbicort | 21 | $13,003 | $619 |
| Incruse Ellipta | 12 | $8,541 | $712 |
| Dulera | 14 | $5,648 | $403 |
| Ventolin Hfa | 65 | $4,655 | $72 |
| Atrovent Hfa | 12 | $4,305 | $359 |
| Ethambutol | 20 | $647 | $32 |
| Azithromycin | 15 | $354 | $24 |
2017: 7 drugs
| Advair Diskus | 24 | $10,839 | $452 |
| Spiriva | 15 | $9,891 | $659 |
| Symbicort | 11 | $6,389 | $581 |
| Ventolin Hfa | 22 | $1,745 | $79 |
| Proair Hfa | 19 | $1,307 | $69 |
| Ethambutol | 14 | $273 | $20 |
| Montelukast | 12 | $103 | $9 |
2016: 26 drugs
| Lantus Solostar | 15 | $7,645 | $510 |
| Crestor | 23 | $6,192 | $269 |
| Advair Diskus | 15 | $5,783 | $386 |
| Proair Hfa | 21 | $1,136 | $54 |
| Ventolin Hfa | 18 | $1,014 | $56 |
| Atorvastatin | 85 | $765 | $9 |
| Valsartan | 22 | $702 | $32 |
| Tamsulosin | 18 | $404 | $22 |
| Chlorthalidone | 11 | $304 | $28 |
| Lisinopril | 62 | $231 | $4 |
| Omeprazole | 38 | $219 | $6 |
| Unifine Pentips | 13 | $213 | $16 |
| Spironolactone | 24 | $169 | $7 |
| Carvedilol | 43 | $161 | $4 |
| Montelukast | 13 | $160 | $12 |
| Levothyroxine | 11 | $146 | $13 |
| Finasteride | 11 | $121 | $11 |
| Furosemide | 51 | $100 | $2 |
| Mirtazapine | 13 | $97 | $7 |
| Losartan | 16 | $95 | $6 |
| Ranitidine | 21 | $81 | $4 |
| Metformin | 22 | $72 | $3 |
| Hydrochlorothiazide | 34 | $67 | $2 |
| Alendronate | 14 | $50 | $4 |
| Amlodipine Besylate | 31 | $50 | $2 |
| Torsemide | 12 | $41 | $3 |
2015: 33 drugs
| Crestor | 49 | $10,506 | $214 |
| Lantus Solostar | 24 | $8,105 | $338 |
| Spiriva | 22 | $7,461 | $339 |
| Novolog Flexpen | 12 | $5,111 | $426 |
| Nexium | 17 | $4,291 | $252 |
| Proair Hfa | 40 | $2,233 | $56 |
| Valsartan | 33 | $1,265 | $38 |
| Ventolin Hfa | 21 | $974 | $46 |
| Atorvastatin | 105 | $955 | $9 |
| Oxybutynin Chloride Er | 12 | $600 | $50 |
| Tamsulosin | 27 | $522 | $19 |
| Unifine Pentips | 29 | $489 | $17 |
| Mirtazapine | 22 | $437 | $20 |
| Lisinopril | 122 | $419 | $3 |
| Ranitidine | 35 | $383 | $11 |
| Chlorthalidone | 13 | $359 | $28 |
| Omeprazole | 49 | $320 | $7 |
| Metoprolol | 18 | $317 | $18 |
| Levothyroxine | 17 | $244 | $14 |
| Spironolactone | 38 | $235 | $6 |
| Metformin | 73 | $229 | $3 |
| Carvedilol | 57 | $218 | $4 |
| Alendronate | 35 | $165 | $5 |
| Hydrochlorothiazide | 63 | $153 | $2 |
| Losartan | 33 | $152 | $5 |
| Montelukast | 17 | $151 | $9 |
| Furosemide | 55 | $138 | $3 |
| Amlodipine Besylate | 55 | $125 | $2 |
| Simvastatin | 35 | $122 | $3 |
| Torsemide | 14 | $88 | $6 |
| Famotidine | 17 | $81 | $5 |
| Gemfibrozil | 12 | $62 | $5 |
| Single Use Swab | 11 | $29 | $3 |
2014: 32 drugs
| Crestor | 38 | $7,215 | $190 |
| Spiriva | 18 | $6,347 | $353 |
| Advair Diskus | 15 | $5,649 | $377 |
| Januvia | 15 | $5,494 | $366 |
| Lantus Solostar | 22 | $5,459 | $248 |
| Diovan | 16 | $2,218 | $139 |
| Valsartan | 12 | $1,734 | $144 |
| Atorvastatin | 47 | $1,679 | $36 |
| Proair Hfa | 24 | $1,176 | $49 |
| Clopidogrel | 16 | $884 | $55 |
| Mirtazapine | 18 | $767 | $43 |
| Oxybutynin Chloride Er | 11 | $711 | $65 |
| Metoprolol | 22 | $426 | $19 |
| Comfort Ez | 17 | $400 | $24 |
| Omeprazole | 44 | $397 | $9 |
| Carvedilol | 52 | $389 | $7 |
| Lisinopril | 94 | $345 | $4 |
| Tamsulosin | 17 | $294 | $17 |
| Spironolactone | 28 | $274 | $10 |
| Ranitidine | 30 | $255 | $9 |
| Alendronate | 38 | $248 | $7 |
| Metformin | 38 | $221 | $6 |
| Amlodipine Besylate | 45 | $199 | $4 |
| Simvastatin | 50 | $199 | $4 |
| Levothyroxine | 16 | $197 | $12 |
| Furosemide | 49 | $194 | $4 |
| Losartan | 15 | $192 | $13 |
| Alcohol Prep Pads | 12 | $179 | $15 |
| Chlorthalidone | 12 | $175 | $15 |
| Hydrochlorothiazide | 35 | $74 | $2 |
| Famotidine | 13 | $61 | $5 |
| Lisinopril-Hydrochlorothiazide | 13 | $54 | $4 |
2013: 29 drugs
| Novolog Mix 70-30 Flexpen | 14 | $5,305 | $379 |
| Novolog | 20 | $4,070 | $204 |
| Crestor | 22 | $3,821 | $174 |
| Lantus Solostar | 18 | $2,940 | $163 |
| Diovan | 14 | $1,700 | $121 |
| Clopidogrel | 17 | $772 | $45 |
| Fluticasone Propionate | 15 | $703 | $47 |
| Proair Hfa | 13 | $603 | $46 |
| Omeprazole | 41 | $593 | $14 |
| Lamotrigine | 11 | $585 | $53 |
| Atorvastatin | 16 | $543 | $34 |
| Losartan | 12 | $342 | $28 |
| Simvastatin | 38 | $327 | $9 |
| Doxazosin Mesylate | 17 | $327 | $19 |
| Carvedilol | 40 | $298 | $7 |
| Alendronate | 24 | $295 | $12 |
| Lisinopril | 52 | $276 | $5 |
| Metformin | 29 | $265 | $9 |
| Chlorthalidone | 20 | $217 | $11 |
| Comfort Ez | 12 | $205 | $17 |
| Amlodipine Besylate | 39 | $198 | $5 |
| Ranitidine | 16 | $177 | $11 |
| Furosemide | 33 | $128 | $4 |
| Ramipril | 11 | $128 | $12 |
| Paroxetine | 11 | $108 | $10 |
| Hydrochlorothiazide | 25 | $59 | $2 |
| Spironolactone | 12 | $50 | $4 |
| Glipizide | 15 | $43 | $3 |
| Atenolol | 15 | $38 | $3 |
Money from drug and device companies
$67 in 2020
A payment is not proof that care is biased.
| United Therapeutics | Remodulin | $67 | 1 payment
|
See the published payment
| United Therapeutics | Meals · 2020-01-17 | Remodulin | $67 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 74.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1407114044
- Licence
- CA A142233California A142233: Current · expires 2027-10-31
- Trained
- Harvard Medical School, 2012 · 14 years ago
- Group
- University of California San Francisco · Regents of the University of California · University Anesthesia Medical Group
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Internal medicine (207R00000X)
- Mailing address
- 513 Parnassus Ave, Hse 1314, San Francisco, CA, 94143
- NPI first listed
- 2012-05-02
- NPI last updated
- 2018-10-17
This is when the NPI record was last certified, not a medical board exam.